391 related articles for article (PubMed ID: 28083667)
1. Use of proton pump inhibitors and mortality after hip fracture in a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2017 May; 28(5):1587-1595. PubMed ID: 28083667
[TBL] [Abstract][Full Text] [Related]
2. Proton pump inhibitor use and the risk of osteoporosis and fracture in stroke patients: a population-based cohort study.
Lin SM; Yang SH; Liang CC; Huang HK
Osteoporos Int; 2018 Jan; 29(1):153-162. PubMed ID: 29032384
[TBL] [Abstract][Full Text] [Related]
3. Antiresorptive therapy and risk of mortality and refracture in osteoporosis-related hip fracture: a nationwide study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Osteoporos Int; 2016 Jan; 27(1):387-96. PubMed ID: 26576544
[TBL] [Abstract][Full Text] [Related]
4. Mortality after hip fracture in Austria 2008-2011.
Brozek W; Reichardt B; Kimberger O; Zwerina J; Dimai HP; Kritsch D; Klaushofer K; Zwettler E
Calcif Tissue Int; 2014 Sep; 95(3):257-66. PubMed ID: 24989776
[TBL] [Abstract][Full Text] [Related]
5. Proton pump inhibitors and risk of hip fracture: a meta-analysis of observational studies.
Poly TN; Islam MM; Yang HC; Wu CC; Li YJ
Osteoporos Int; 2019 Jan; 30(1):103-114. PubMed ID: 30539272
[TBL] [Abstract][Full Text] [Related]
6. A survey of outcomes and management of patients post fragility fractures in China.
Wang O; Hu Y; Gong S; Xue Q; Deng Z; Wang L; Liu H; Tang H; Guo X; Chen J; Jia X; Xu Y; Lan L; Lei C; Dong H; Yuan G; Fu Q; Wei Y; Xia W; Xu L
Osteoporos Int; 2015 Nov; 26(11):2631-40. PubMed ID: 25966892
[TBL] [Abstract][Full Text] [Related]
7. Use of proton pump inhibitors is associated with fractures in young adults: a population-based study.
Freedberg DE; Haynes K; Denburg MR; Zemel BS; Leonard MB; Abrams JA; Yang YX
Osteoporos Int; 2015 Oct; 26(10):2501-7. PubMed ID: 25986385
[TBL] [Abstract][Full Text] [Related]
8. The effect of proton pump inhibitors on fracture risk: report from the Canadian Multicenter Osteoporosis Study.
Fraser LA; Leslie WD; Targownik LE; Papaioannou A; Adachi JD;
Osteoporos Int; 2013 Apr; 24(4):1161-8. PubMed ID: 22890365
[TBL] [Abstract][Full Text] [Related]
9. Length of hospital stay after hip fracture surgery and 1-year mortality.
Yoo J; Lee JS; Kim S; Kim BS; Choi H; Song DY; Kim WB; Won CW
Osteoporos Int; 2019 Jan; 30(1):145-153. PubMed ID: 30361752
[TBL] [Abstract][Full Text] [Related]
10. Proton pump inhibitors and fracture risk. The HUNT study, Norway.
Hoff M; Skovlund E; Skurtveit S; Meyer HE; Langhammer A; Søgaard AJ; Syversen U; Forsmo S; Abrahamsen B; Schei B
Osteoporos Int; 2020 Jan; 31(1):109-118. PubMed ID: 31741023
[TBL] [Abstract][Full Text] [Related]
11. All-cause mortality with current and past use of antidepressants or benzodiazepines after major osteoporotic and hip fracture.
de Bruin IJA; Klop C; Wyers CE; Overbeek JA; Geusens PPMM; van den Bergh JPW; Driessen JHM; de Vries F
Osteoporos Int; 2019 Mar; 30(3):573-581. PubMed ID: 30737577
[TBL] [Abstract][Full Text] [Related]
12. Higher dose but not low dose proton pump inhibitors are associated with increased risk of subsequent hip fractures after first hip fracture: A nationwide observational cohort study.
Brozek W; Reichardt B; Zwerina J; Dimai HP; Klaushofer K; Zwettler E
Bone Rep; 2019 Jun; 10():100204. PubMed ID: 30993153
[TBL] [Abstract][Full Text] [Related]
13. Comparing proton pump inhibitors with histamin-2 receptor blockers regarding the risk of osteoporotic fractures: a nested case-control study of more than 350,000 Korean patients with GERD and peptic ulcer disease.
Park JH; Lee J; Yu SY; Jung JH; Han K; Kim DH; Rhee J
BMC Geriatr; 2020 Oct; 20(1):407. PubMed ID: 33059626
[TBL] [Abstract][Full Text] [Related]
14. Study of the association between hip fracture and acid-suppressive drug use in a UK primary care setting.
Cea Soriano L; Ruigómez A; Johansson S; García Rodríguez LA
Pharmacotherapy; 2014 Jun; 34(6):570-81. PubMed ID: 24634193
[TBL] [Abstract][Full Text] [Related]
15. A population-based case-control study: proton pump inhibition and risk of hip fracture by use of bisphosphonate.
Lee J; Youn K; Choi NK; Lee JH; Kang D; Song HJ; Park BJ
J Gastroenterol; 2013 Sep; 48(9):1016-22. PubMed ID: 23307040
[TBL] [Abstract][Full Text] [Related]
16. The use of proton pump inhibitors in an Italian hospital: focus on oncologic and critical non-ICU patients.
Meli M; Raffa MP; Malta R; Morreale I; Aprea L; D'Alessandro N
Int J Clin Pharm; 2015 Dec; 37(6):1152-61. PubMed ID: 26319396
[TBL] [Abstract][Full Text] [Related]
17. Long-term proton pump inhibitor therapy and risk of hip fracture.
Yang YX; Lewis JD; Epstein S; Metz DC
JAMA; 2006 Dec; 296(24):2947-53. PubMed ID: 17190895
[TBL] [Abstract][Full Text] [Related]
18. Proton-pump inhibitors and risk of fractures: an update meta-analysis.
Zhou B; Huang Y; Li H; Sun W; Liu J
Osteoporos Int; 2016 Jan; 27(1):339-47. PubMed ID: 26462494
[TBL] [Abstract][Full Text] [Related]
19. Proton pump inhibitor use and risk of hip fractures in patients without major risk factors.
Kaye JA; Jick H
Pharmacotherapy; 2008 Aug; 28(8):951-9. PubMed ID: 18657011
[TBL] [Abstract][Full Text] [Related]
20. One-year clinical outcome in patients with acute coronary syndrome treated with concomitant use of clopidogrel and proton pump inhibitors: results from a regional cohort study.
Ortolani P; Marino M; Marzocchi A; De Palma R; Branzi A
J Cardiovasc Med (Hagerstown); 2012 Dec; 13(12):783-9. PubMed ID: 21252697
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
